Product
Peginterferon beta-1a
Aliases
BIIB017, PEG IFN β-1a, peginterferon beta-1a, PEGylated Interferon Beta-1a (1 other aliases)
Name
Plegridy
INN Name
peginterferon beta-1a
FDA Approved
Yes
4 clinical trials
1 organization
4 indications
1 document
Indication
Multiple SclerosisIndication
Healthy SubjectsIndication
pharmacokineticsIndication
pharmacodynamicsClinical trial
Multicenter Interventional Phase IV Study for the Assessment of the Effects on Patient's Satisfaction of Plegridy (Pre-filled Pen) in Subjects With Relapsing-remitting Multiple Sclerosis Unsatisfied With Other Injectable Subcutaneous Interferons (PLATINUM)Status: Completed, Estimated PCD: 2017-10-02
Clinical trial
Plegridy™ (Peginterferon β-1a) Real World Effectiveness and Safety Observational ProgramStatus: Completed, Estimated PCD: 2022-01-20
Clinical trial
Pregnancy Outcomes in Women Exposed to Diroximel FumarateStatus: Recruiting, Estimated PCD: 2031-01-17
Clinical trial
Pharmacodynamic Biomarkers to Support Biosimilar Development: Clinical Study 3 - Interferon Beta-1A and Peginterferon Beta-1AStatus: Completed, Estimated PCD: 2021-01-26
Document
DailyMed Label: PlegridyOrganization
Biogen Inc.